Climb Bio (NASDAQ:CLYM) Given New $17.00 Price Target at Wedbush

Climb Bio (NASDAQ:CLYM) had its target price raised by Wedbush from $15.00 to $17.00 in a report released on Friday, MarketBeat reports. They currently have an outperform rating on the stock.

Other equities analysts have also recently issued reports about the company. B. Riley Financial assumed coverage on Climb Bio in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Chardan Capital assumed coverage on Climb Bio in a report on Tuesday. They set a “buy” rating and a $22.00 price objective for the company. Truist Financial assumed coverage on Climb Bio in a report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price objective for the company. Mizuho assumed coverage on Climb Bio in a report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, Piper Sandler assumed coverage on Climb Bio in a report on Friday, February 13th. They set an “overweight” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $19.80.

Climb Bio Stock Performance

Shares of CLYM stock opened at $11.37 on Friday. The stock has a fifty day moving average price of $7.90 and a 200 day moving average price of $5.08. The stock has a market cap of $543.14 million, a PE ratio of -14.58 and a beta of 0.02. Climb Bio has a 1 year low of $1.13 and a 1 year high of $12.48.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06. As a group, equities research analysts predict that Climb Bio will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On Climb Bio

Hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new position in Climb Bio during the fourth quarter worth $306,000. Virtu Financial LLC purchased a new position in Climb Bio during the fourth quarter worth $43,000. Balyasny Asset Management L.P. purchased a new position in Climb Bio during the fourth quarter worth $57,000. Blair William & Co. IL purchased a new position in Climb Bio during the fourth quarter worth $44,000. Finally, Qube Research & Technologies Ltd purchased a new position in Climb Bio during the second quarter worth $43,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.